DUX4 and facioscapulohumeral muscular dystrophy: The p38 inhibitor Losmapimod, recently tested in a Phase 2 clinical trial for FSHD patients (ClinicalTrials.gov Identifier: NCT04003974) has been shown to decrease the expression of DUX4 and its target genes in a mouse xenograft model27.